

EVIDENCE-BASED REVIEW OF SGLT2 INHIBITORS: INSIGHTS FROM CLINICAL TRIALS IN MULTISYSTEM DISEASE MANAGEMENT

Ragul Ezhumalai*, Pavithran G., Ragu Ram C. R., Sivaramaswamy N., Dharma M., Subaneshwaran S.

Clinical Pharmacist Intern, Department of Clinical Pharmacy, Karpagam College of Pharmacy, Coimbatore, Tamil Nadu, India.

Article Received on
05 May 2025,

Revised on 25 May 2025,
Accepted on 15 June 2025

<https://doi.org/10.5281/zenodo.21390035>



***Corresponding Author**

Ragul Ezhumalai

Clinical Pharmacist Intern,
Department of Clinical
Pharmacy, Karpagam
College of Pharmacy,
Coimbatore, Tamil Nadu,
India.

ABSTRACT

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed for glycemic control in type 2 diabetes (T2D), have emerged as a groundbreaking class of medications due to their profound and consistent cardiovascular and renal benefits. This review synthesizes the current understanding of SGLT2 inhibitors' mechanisms of action, approved agents, clinical pharmacology, and established therapeutic roles in T2D, heart failure (HF), and chronic kidney disease (CKD). Beyond their primary effect of increasing renal glucose excretion, SGLT2 inhibitors exert pleiotropic effects, including hemodynamic improvements (e.g., reduced intraglomerular pressure, plasma volume reduction), metabolic shifts (e.g., enhanced ketone body utilization), and anti-inflammatory/anti-fibrotic properties. Pivotal clinical trials have demonstrated significant reductions in cardiovascular death, hospitalization for heart failure across the ejection fraction spectrum (HFrEF and HFpEF), and progression of CKD (including end-stage kidney disease) in patients with and without

T2D. While generally well-tolerated, common adverse effects include genitourinary infections and a rare risk of euglycemic diabetic ketoacidosis. The clinical pharmacist plays a vital role in patient education, drug interaction management, and monitoring parameters to optimize therapy. Future applications may extend to broader cardiorenal protection, obesity, non-alcoholic fatty liver disease, and polycystic kidney disease. SGLT2 inhibitors represent a

triple threat against interconnected cardiometabolic and renal diseases, fundamentally reshaping evidence-based clinical practice and improving patient outcomes.

KEYWORDS: SGLT2 inhibitors, Type 2 diabetes, Heart failure, Chronic kidney disease, Cardiorenal protection, Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin.

INTRODUCTION

Diabetes mellitus (DM), heart failure (HF), and chronic kidney disease (CKD) represent a formidable and growing global health burden, often coexisting and profoundly influencing each other's progression and prognosis.^[1,2,3] The intricate interconnections among these conditions necessitate a holistic and integrated therapeutic approach to mitigate their devastating impact on morbidity, mortality, and healthcare costs.^[4,6]

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of oral antihyperglycemic agents initially developed for the management of type 2 diabetes (T2D).^[5,8,22] Their primary mechanism of action involves inhibiting SGLT2 in the renal proximal tubules, leading to increased urinary glucose excretion, improved glycemic control, and modest weight reduction.^[20,21]

Beyond their glycemic effects, a series of pivotal clinical trials have unveiled compelling evidence of significant cardiorenal protective benefits associated with SGLT2 inhibitors, fundamentally altering treatment paradigms.^[13,15,17,19,23] These trials have consistently demonstrated the ability of SGLT2 inhibitors to reduce the risk of cardiovascular death, hospitalization for heart failure, and the progression of kidney disease across a wide spectrum of patients, including those with and without type 2 diabetes.

This remarkable expansion of their therapeutic utility has established SGLT2 inhibitors as a "triple threat" against diabetes, heart failure, and chronic kidney disease. Their pleiotropic mechanisms, which extend beyond glycosuria to encompass improvements in renal hemodynamic, metabolic shifts, and anti-inflammatory effects, underscore their multifaceted Reno protective and cardioprotective actions.^[20,21,25,31] The widespread adoption of SGLT2 inhibitors reflects a transformative shift in the integrated management of these complex chronic conditions, advocating for comprehensive patient care.

This review article aims to provide a comprehensive overview of the current understanding of SGLT2 inhibitors in clinical practice, exploring their established efficacy, safety profiles, and

evolving roles in the integrated management of type 2 diabetes, heart failure, and chronic kidney disease, based on the latest evidence.

MECHANISM OF ACTION

Sodium-glucose co-transporter 2 (SGLT2) inhibitors exert their therapeutic effects primarily through their action on the kidneys, but their benefits extend far beyond simple glycemic control via a complex interplay of mechanisms.

1. Renal Glucose Excretion

The primary and initial mechanism of action for SGLT2 inhibitors involves the selective and reversible inhibition of the SGLT2 protein, located almost exclusively in the S1 segment of the renal proximal tubule.^[20,21] Under normal physiological conditions, SGLT2 is responsible for reabsorbing approximately 90% of the filtered glucose from the glomerular filtrate back into the systemic circulation.^[21] By inhibiting SGLT2, these agents reduce the renal reabsorption of glucose, leading to increased urinary glucose excretion (glucosuria).^[20] This glucose loss results in a reduction in plasma glucose concentrations, improved glycemic control in patients with type 2 diabetes, and a modest reduction in body weight due to caloric loss.^[20,21]

2. Cardiorenal Protective Mechanisms (Beyond Glycemic Control)

The significant cardiorenal benefits observed with SGLT2 inhibitors, particularly in patients with heart failure and chronic kidney disease, extend beyond their glucose-lowering effects and are attributed to a multitude of pleiotropic mechanisms^[1,2,3,25,31]:

❖ Hemodynamic Effects

- **Intraglomerular Pressure Reduction:** SGLT2 inhibition leads to increased sodium and glucose delivery to the macula densa in the distal tubule. This sensing by the macula densa triggers a tubuloglomerular feedback (TGF) response, resulting in afferent arteriolar vasoconstriction.^[20,21] This vasoconstriction reduces intraglomerular pressure, which is crucial for kidney protection, especially in conditions like diabetes where glomerular hyperfiltration and hypertension contribute to kidney damage.^[20,21]
- **Reduced Plasma Volume:** Glucosuria and natriuresis (increased sodium excretion) induced by SGLT2 inhibitors lead to a mild osmotic diuresis, resulting in a reduction in plasma volume.^[21] This effect contributes to decreased cardiac preload and afterload, which is beneficial in heart failure by reducing ventricular wall stress and congestion.^[26]

❖ Metabolic Reprogramming

- **Shift in Fuel Utilization:** SGLT2 inhibitors promote a shift in myocardial and renal energy metabolism from glucose oxidation towards increased utilization of ketone bodies (e.g., β -hydroxybutyrate) as an energy substrate.^[20] Ketone bodies are a more energy-efficient fuel source for the heart and kidneys, leading to improved cardiac and renal bioenergetics and efficiency, especially in conditions of impaired glucose utilization.^[20]
- **Reduced Insulin Resistance:** While primarily observed in diabetic patients, SGLT2 inhibitors can contribute to improved insulin sensitivity, which further contributes to metabolic benefits.^[8]

❖ Direct Organ Effects and Anti-inflammatory Properties

- **Reduced Inflammation and Oxidative Stress:** SGLT2 inhibitors have been shown to possess anti-inflammatory and anti-oxidative stress properties, which can mitigate organ damage in the heart and kidneys.^[25,31] They can reduce pro-inflammatory cytokines and markers of oxidative stress, thereby protecting tissues from damage.^[25]
- **Anti-fibrotic Effects:** Emerging evidence suggests SGLT2 inhibitors may exert anti-fibrotic effects in both cardiac and renal tissues, counteracting the pathological remodelling associated with heart failure and CKD progression.^[25]
- **Improved Endothelial Function:** Some studies indicate that SGLT2 inhibitors can improve endothelial function, contributing to cardiovascular health.^[29]

APPROVED SGLT2 INHIBITORS

Several SGLT2 inhibitors have gained regulatory approval worldwide for the treatment of type 2 diabetes, and increasingly, for cardiovascular and renal indications. The most widely used agents in this class include:

- **DAPAGLIFLOZIN:** Approved for T2D, heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), and CKD, regardless of the presence of T2D.^[1, 6, 17, 18, 26]
- **EMPAGLIFLOZIN:** Approved for T2D, HFrEF and HFpEF, and CKD, regardless of the presence of T2D.^[2,3,7,14,16,24,27,28]
- **CANAGLIFLOZIN:** Approved for T2D, and to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease, and to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for HF in adults with T2D and diabetic nephropathy.^[4,9,10,11,15,19,23]

- **ERTUGLIFLOZIN:** Primarily approved for the treatment of T2D, with cardiovascular outcomes data demonstrating non-inferiority for major adverse cardiovascular events in T2D patients.^[12,13]

CLINICAL PHARMACOLOGY

The clinical pharmacology of SGLT2 inhibitors is characterized by their oral bioavailability, selective SGLT2 inhibition, and renal elimination.

1. Absorption and Bioavailability

SGLT2 inhibitors are generally well absorbed after oral administration, with peak plasma concentrations typically achieved within 1-2 hours. Food intake has a minimal effect on their absorption, allowing for administration with or without meals.^[5,8]

2. Distribution

These agents exhibit moderate to high protein binding in plasma, which contributes to their distribution throughout the body. Their volume of distribution is generally consistent with extravascular distribution.^[5,8]

3. Metabolism and Excretion

SGLT2 inhibitors undergo hepatic metabolism, primarily via uridine diphosphate glucuronosyltransferase (UGT) enzymes, leading to the formation of inactive glucuronide conjugates.^[20] These inactive metabolites are then predominantly excreted via the kidneys and, to a lesser extent, in feces.^[20,21] Due to their renal elimination, dose adjustments may be necessary in patients with severe renal impairment, although their cardiorenal benefits extend across a wide range of estimated glomerular filtration rates (eGFR).^[1,4,6,7]

4. Pharmacodynamics

The pharmacodynamic effects of SGLT2 inhibitors, such as increased urinary glucose excretion, are dose-dependent and correlate with their plasma concentrations. The inhibition of SGLT2 is sustained over a 24-hour period, supporting once-daily dosing for most agents.^[20,21] The extent of glucosuria is dependent on the filtered glucose load and residual renal function; therefore, their glucose-lowering efficacy diminishes as kidney function declines, even though their cardiorenal protective effects may persist.^[4,7,28]

THERAPEUTIC ROLE IN TYPE 2 DIABETES MELLITUS

SGLT2 inhibitors have emerged as a cornerstone in the management of type 2 diabetes (T2D), significantly impacting glycemic control and offering substantial improvements in cardiovascular and renal outcomes.

1. Glycemic Control

As initially approved agents for T2D, SGLT2 inhibitors effectively lower blood glucose levels by increasing urinary glucose excretion, independent of insulin secretion or action.^[20,21,22] This mechanism provides a sustained reduction in HbA1c (glycated haemoglobin), typically ranging from 0.5% to 1.0%, with a low risk of hypoglycaemia when used as monotherapy or in combination with other agents that do not induce hypoglycaemia (e.g., metformin).^[5,8] Beyond HbA1c reduction, they also contribute to modest weight loss and a reduction in blood pressure, both of which are beneficial comorbidities in T2D patients.^[20,21]

2. Cardiovascular Outcomes

Beyond their glycemic benefits, the most transformative impact of SGLT2 inhibitors in T2D has been their demonstrated ability to reduce Major Adverse Cardiovascular Events (MACE). Large-scale Cardiovascular Outcome Trials (CVOTs) have consistently shown a significant reduction in MACE (e.g., cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in patients with T2D, particularly those with established cardiovascular disease or multiple cardiovascular risk factors.^[13,15,19,23] Notably, the reduction in hospitalization for heart failure (HHF) has been a consistent and prominent finding across all SGLT2 inhibitors studied in T2D populations, regardless of a history of HF.^[1,2,3,14,16,24,26,27] These benefits extend beyond glycemic control and are attributed to their pleiotropic cardiorenal mechanisms.^[25,31]

3. Renal Outcomes

SGLT2 inhibitors have also profoundly altered the management of diabetic kidney disease (DKD). Clinical trials have shown that these agents significantly reduce the risk of kidney disease progression, including a reduction in the decline of estimated glomerular filtration rate (eGFR), reduction in albuminuria, and a lower risk of end-stage kidney disease (ESKD) or renal death in patients with T2D.^[4,6,7,9,10,11,28] This Reno protective effect is observed across a range of kidney function levels and is independent of their glucose-lowering effects, primarily driven by their beneficial hemodynamic and metabolic actions on the kidney.

CARDIOVASCULAR BENEFITS AND HEART FAILURE MANAGEMENT

The discovery of the profound cardiovascular benefits of SGLT2 inhibitors has revolutionized the management of patients with and without type 2 diabetes, particularly those with heart failure (HF).

1. Reduction in Hospitalization for Heart Failure (HHF)

One of the most striking and consistent findings across major SGLT2 inhibitor outcome trials has been a significant reduction in the risk of hospitalization for heart failure (HHF) and cardiovascular death^[1,2,3,14,16,17,24,26,27] This benefit has been observed in:

- **Patients with Type 2 Diabetes and Established CVD:** Trials like EMPA-REG OUTCOME (empagliflozin), CANVAS Program (canagliflozin), and DECLARE-TIMI 58 (dapagliflozin) demonstrated a substantial reduction in HHF in T2D patients with or at high risk for atherosclerotic cardiovascular disease.^[13,15,19,23]
- **Patients with Heart Failure with Reduced Ejection Fraction (HFrEF):** The DAPA-HF (dapagliflozin) and EMPEROR-Reduced (empagliflozin) trials clearly established SGLT2 inhibitors as foundational therapy for HFrEF, regardless of T2D status. These trials showed significant reductions in cardiovascular death and worsening HF events, including HHF.^[1,2,17,26,27]
- **Patients with Heart Failure with Preserved Ejection Fraction (HFpEF):** More recently, EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) demonstrated similar benefits in HFpEF, a population with limited therapeutic options, showing reduced HHF and cardiovascular death. This was a landmark finding, extending the role of SGLT2 inhibitors across the entire spectrum of HF.^[3,6,14,16,18,24]

2. Mechanisms Underlying Cardiovascular Benefits in HF

The cardiovascular benefits of SGLT2 inhibitors in heart failure are multifactorial and go beyond their glycemic effects, primarily driven by the pleiotropic mechanisms discussed previously.^[20,21,25,31] Key contributions include:

- **Hemodynamic Optimization:** Reduction in plasma volume (due to osmotic diuresis) leads to decreased cardiac preload and afterload, alleviating congestion and reducing ventricular wall stress.^[21,26]
- **Improved Myocardial Energetics:** The shift towards ketone body utilization as a more efficient fuel source for the heart directly improves cardiac bioenergetics, especially in the stressed myocardium of HF patients.^[20]

- **Anti-inflammatory and Anti-fibrotic Effects:** Reduction in inflammation, oxidative stress, and myocardial fibrosis contributes to improved cardiac structure and function, counteracting adverse remodelling in HF.^[25]
- **Renal Protection:** By preserving renal function, SGLT2 inhibitors help prevent the vicious cycle of cardiorenal syndrome, where worsening kidney function exacerbates HF and vice versa.^[4,7]

3. Clinical Implications for HF Management

Given the robust evidence, SGLT2 inhibitors are now recommended as a cornerstone therapy for all patients with HFrEF, regardless of T2D status, and for HFpEF, as per major international guidelines.^[1,2,3,6] Their early initiation in appropriate patients with HF can significantly improve clinical outcomes, reduce hospitalizations, and enhance quality of life. This class of drugs represents a significant advancement in the comprehensive management of heart failure, complementing existing therapies.

RENO PROTECTIVE EFFECTS IN CKD

The demonstrated Reno protective effects of SGLT2 inhibitors represent a paradigm shift in the management of chronic kidney disease (CKD), extending benefits beyond those seen in diabetic kidney disease to a broader CKD population.

1. Reduction in CKD Progression

Large-scale clinical trials have unequivocally demonstrated that SGLT2 inhibitors significantly slow the progression of CKD, reduce the risk of kidney failure, and decrease the incidence of kidney-specific composite outcomes (e.g., sustained decline in eGFR, end-stage kidney disease, renal death).^[1,4,6,7,9,10,11,28] This benefit is observed in patients with and without type 2 diabetes, highlighting a kidney-specific effect independent of glycemic control.^[1,6,7,28] Key trials supporting this include:

- **CREDENCE (canagliflozin):** Specifically designed for patients with T2D and CKD, showing a significant reduction in renal and cardiovascular events.^[4,9,10,11]
- **DAPA-CKD (dapagliflozin):** A landmark trial that demonstrated substantial renoprotection in patients with CKD, with or without T2D, establishing dapagliflozin as a foundational therapy for CKD management.^[1,6,18,28]
- **EMPA-KIDNEY (empagliflozin):** Further solidified the role of empagliflozin in a broad CKD population, irrespective of T2D status, showing significant reduction in kidney disease progression or cardiovascular death.^[7,28]

2. Mechanisms Underlying Renoprotection

The Reno protective effects of SGLT2 inhibitors are complex and multifaceted, primarily driven by:

- **Restoration of Tubuloglomerular Feedback (TGF):** By inhibiting SGLT2, these agents increase sodium delivery to the macula densa, which triggers afferent arteriolar vasoconstriction and reduces elevated intraglomerular pressure (glomerular hyperfiltration).^[20,21] This reduction in pressure is a crucial mechanism for protecting the delicate glomerular capillaries from damage, particularly in diabetic nephropathy.^[20]
- **Reduction in Albuminuria:** SGLT2 inhibitors consistently demonstrate a reduction in albuminuria (protein in the urine), an important marker and mediator of CKD progression. This effect is thought to be a consequence of reduced intraglomerular pressure and potentially direct effects on podocytes and the glomerular basement membrane.^[4,7,28]
- **Anti-inflammatory and Anti-fibrotic Effects:** As previously discussed, SGLT2 inhibitors exert anti-inflammatory and anti-fibrotic actions within the kidney, which can mitigate chronic injury and scarring, thereby preserving renal structure and function over time.^[25,31]
- **Metabolic Effects:** Improvements in metabolic parameters, such as reduced oxidative stress and improved fatty acid oxidation, may also contribute to the overall Reno protective profile.^[20,25]

3. Clinical Implications for CKD Management

The compelling evidence from large-scale clinical trials has led to the inclusion of SGLT2 inhibitors in major clinical guidelines as a recommended therapy for patients with CKD, especially those with albuminuria, regardless of their diabetic status.^[1,4,6,7,28] Their early and sustained use can significantly delay CKD progression, reduce the risk of kidney failure requiring dialysis or transplantation, and lower the burden of associated cardiovascular complications. This makes SGLT2 inhibitors a critical component of multidisciplinary CKD management.

SAFETY PROFILE AND ADVERSE EFFECTS

While SGLT2 inhibitors are generally well-tolerated and offer significant benefits, it is crucial to be aware of their safety profile and potential adverse effects. The most commonly

reported side effects are directly related to their mechanism of action (glucosuria and diuresis).

1. Genitourinary Infections

Increased glucose in the urine creates a favourable environment for bacterial and fungal growth, leading to a higher incidence of genitourinary infections.

- **Genital mycotic infections (GMIs):** These are the most common adverse events, particularly in women, including vulvovaginal candidiasis. Men may experience balanitis or balanoposthitis.^[5,8,22] These infections are typically mild to moderate in severity and respond to standard antifungal or antibiotic treatment.
- **Urinary tract infections (UTIs):** While initially a concern, large clinical trials have not consistently shown a significant increase in serious or complicated UTIs with SGLT2 inhibitors, though a slight increase in uncomplicated UTIs may occur.^[5,8,22]

2. Volume Depletion and Hypotension

The osmotic diuretic effect of SGLT2 inhibitors can lead to mild volume depletion, which may manifest as orthostatic hypotension, particularly in elderly patients, those on diuretics, or those with impaired renal function.^[5,8] Careful monitoring of blood pressure and fluid status is recommended, especially upon initiation of therapy.

3. Diabetic Ketoacidosis (DKA)

Although rare, a significant concern with SGLT2 inhibitors, particularly in patients with type 1 diabetes (off-label use) or those with type 2 diabetes under specific circumstances, is the risk of euglycemic diabetic ketoacidosis (euDKA).^[25,30] EuDKA is characterized by normal or only mildly elevated glucose levels despite significant ketosis and acidosis. Risk factors include acute illness, surgery, reduced carbohydrate intake, excessive alcohol consumption, and significant insulin dose reduction. Patients should be educated on the symptoms of DKA and instructed to seek immediate medical attention if they occur. Temporary discontinuation of the SGLT2 inhibitor before major surgery or during acute severe illness is often recommended (sick day rules).^[25]

4. Acute Kidney Injury (AKI)

While SGLT2 inhibitors are Renoprotective long-term, a transient dip in estimated glomerular filtration rate (eGFR) may be observed upon initiation, particularly in those with pre-existing CKD or those on concomitant renin-angiotensin system inhibitors or

diuretics.^[4,7,28] This initial reduction is generally reversible and reflects the beneficial hemodynamic effect of reducing intraglomerular pressure. However, in cases of severe volume depletion or acute illness, AKI can occur. Close monitoring of renal function, particularly in the initial weeks of treatment, is prudent.^[4,7,28]

5. Fractures and Amputations (Canagliflozin Specific)

Early data from the CANVAS Program raised a signal for an increased risk of lower limb amputations (primarily toes and feet) with canagliflozin, and some SGLT2 inhibitors showed a numerical imbalance in fracture risk.^[15,23] Subsequent large-scale trials with other SGLT2 inhibitors and meta-analyses have generally not replicated these findings as a class effect. However, vigilance for foot care in patients with diabetes, particularly those with pre-existing peripheral artery disease or neuropathy, remains important.^[15,23]

6. Fournier's Gangrene

A rare but serious adverse event, Fournier's gangrene (necrotizing fasciitis of the perineum), has been reported with SGLT2 inhibitor use. While extremely uncommon, patients should be educated on the symptoms (e.g., pain, tenderness, redness, swelling in the genital or perineal area with fever) and advised to seek urgent medical attention if these symptoms develop.^[1,2,3]

Overall, the extensive clinical trial data and real-world experience confirm that the benefits of SGLT2 inhibitors in reducing cardiovascular and renal events largely outweigh their risks in appropriate patient populations, provided prescribers and patients are aware of and manage potential adverse effects.

DRUG INTERACTIONS AND MONITORING PARAMETERS

Effective and safe clinical practice with SGLT2 inhibitors necessitates an understanding of potential drug interactions and key monitoring parameters.

1. Drug Interactions

SGLT2 inhibitors generally have a low risk of drug-drug interactions due to their metabolic pathways, which primarily involve glucuronidation rather than extensive cytochrome P450 enzyme metabolism. However, certain interactions warrant consideration:

- **Diuretics:** Co-administration with loop or thiazide diuretics may enhance the diuretic effect of SGLT2 inhibitors, potentially increasing the risk of volume depletion,

dehydration, and hypotension.^[5,8] Close monitoring of fluid status, blood pressure, and renal function is advisable, and dose adjustments of diuretics may be necessary.

- **Insulin and Insulin Secretagogues (Sulfonylureas):** When SGLT2 inhibitors are used in combination with insulin or insulin secretagogues, the risk of hypoglycaemia may increase. To mitigate this, a dose reduction of insulin or the insulin secretagogue might be required upon initiation of SGLT2 inhibitor therapy.^[5,8,22]
- **Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors:** While SGLT2 inhibitors provide additive renoprotection with RAAS inhibitors (e.g., ACE inhibitors, ARBs), their combined use can lead to an initial, transient decline in eGFR.^[4,7,28] This is generally an expected hemodynamic effect rather than true kidney injury, but close monitoring of renal function is important, especially in the first few weeks of co-initiation.

2. Monitoring Parameters

Regular monitoring is essential to ensure the safety and efficacy of SGLT2 inhibitor therapy:

- **Renal Function (eGFR and Serum Creatinine)**
 - ❖ **Baseline and Regular Monitoring:** eGFR should be assessed prior to initiating SGLT2 inhibitors and periodically thereafter, typically within 1-2 weeks of initiation and then at least annually, or more frequently in patients with rapidly declining eGFR or those on concomitant nephrotoxic agents.^[1,4,6,7,28]
 - ❖ **Initial eGFR Dip:** Patients should be counselled about a potential initial, modest, and generally reversible dip in eGFR upon starting therapy. This often reflects the beneficial reduction in intraglomerular pressure.^[28]
 - ❖ **Discontinuation Thresholds:** Specific eGFR thresholds exist for initiation and continuation of SGLT2 inhibitors for their glycemic, cardiovascular, and renal indications. For example, while glucose-lowering efficacy wanes at lower eGFRs, cardiorenal benefits generally persist down to specific eGFR cutoffs (e.g., eGFR ≥ 20 mL/min/1.73 m² for some CKD indications).^[1,4,6,7,28]
- **Blood Pressure:** Due to their osmotic diuretic effect, SGLT2 inhibitors can lower blood pressure. Monitoring blood pressure, especially for orthostatic changes, is important, particularly in high-risk individuals.^[5,8]
- **Volume Status:** Assessment for signs and symptoms of volume depletion (e.g., dizziness, light-headedness, dry mouth) is important, particularly in elderly patients or those concomitantly receiving diuretics.^[5,8]

- **Glycemic Control (HbA1c):** For patients with diabetes, HbA1c should be monitored to assess glycemic efficacy, though the primary rationale for SGLT2 inhibitor use may be cardiorenal protection irrespective of baseline HbA1c.^[5,8]
- **Symptoms of Genitourinary Infections:** Patients should be educated to recognize and report symptoms of genital mycotic infections (e.g., itching, discharge, pain) or urinary tract infections (e.g., dysuria, frequency, urgency).^[5,8,22]
- **Symptoms of Diabetic Ketoacidosis (DKA):** Patients (especially those with T2D, T1D on off-label use, or during acute illness/surgery) must be educated on the symptoms of DKA (e.g., nausea, vomiting, abdominal pain, fatigue, shortness of breath) and advised to seek immediate medical attention if these occur.^[25]
- **Foot Examination:** Regular foot examination is recommended, particularly for patients with diabetes and risk factors for peripheral artery disease or neuropathy, in light of the historical amputation signal with canagliflozin.^[15,23]

CLINICAL PHARMACIST'S ROLE IN OPTIMIZING SGLT2 THERAPY

Clinical pharmacists play a pivotal role in optimizing the safe and effective use of SGLT2 inhibitors in diverse patient populations. Their expertise in pharmacotherapy, drug interactions, and patient education makes them invaluable members of the healthcare team, particularly given the broad indications and complex considerations associated with SGLT2 inhibitors.

1. Patient Education and Counselling

Pharmacists are at the forefront of educating patients about SGLT2 inhibitors, covering crucial aspects such as:

- **Mechanism of Action and Expected Benefits:** Explaining how the medication works to manage diabetes, heart failure, and CKD, and outlining the cardiovascular and renal protective benefits.^[1,2,3,5,8]
- **Administration and Adherence:** Providing clear instructions on proper dosing, timing, and consistency of medication intake.
- **Adverse Effect Management:** Counselling on common side effects like genitourinary infections (including hygiene practices to reduce risk), symptoms of volume depletion, and especially the rare but serious risk of euglycemic DKA. This includes instructing patients on "sick day rules" and when to seek urgent medical attention.^[25]

- **Lifestyle Modifications:** Reinforcing the importance of diet, exercise, and fluid management as complementary strategies to pharmacotherapy.

2. Comprehensive Medication Review and Drug Interaction Management

Pharmacists conduct thorough medication reviews to identify potential drug interactions and optimize medication regimens. This includes:

- **Diuretic Adjustments:** Recommending dose adjustments for concomitant diuretics to mitigate the risk of excessive volume depletion and hypotension, especially when initiating SGLT2 inhibitors or during periods of acute illness.^[5,8]
- **Hypoglycemia Risk Management:** Advising on appropriate dose reductions of insulin or insulin secretagogues when co-prescribed with SGLT2 inhibitors to minimize the risk of hypoglycemia.^[5,8,22]
- **RAAS Inhibitor Co-therapy:** Monitoring renal function when SGLT2 inhibitors are co-initiated with RAAS inhibitors, acknowledging the expected initial eGFR dip and ensuring it is not indicative of true kidney injury.^[4,7,28]
- **Identifying Contraindications:** Screening for contraindications, such as severe renal impairment beyond approved eGFR thresholds, or history of DKA in patients without T2D.

3. Monitoring and Dose Optimization

Pharmacists contribute significantly to monitoring patient response and safety:

- **Renal Function Monitoring:** Reviewing eGFR and serum creatinine trends, interpreting changes, and recommending dose adjustments or temporary discontinuation based on clinical guidelines and patient status.^[1,4,6,7,28]
- **Blood Pressure and Volume Status:** Assessing blood pressure readings and advising patients on self-monitoring for signs of hypotension or dehydration.
- **Glycemic Assessment:** For diabetic patients, evaluating HbA1c and blood glucose trends to ensure therapeutic goals are met while minimizing hypoglycemia risk.
- **Adverse Event Surveillance:** Proactively inquiring about and identifying signs and symptoms of adverse effects, including genitourinary infections, and facilitating timely management.

4. Collaborative Practice and Team-Based Care

Clinical pharmacists actively participate in multidisciplinary healthcare teams, fostering collaborative patient care:

- **Interprofessional Communication:** Liaising with physicians, nurses, dietitians, and other healthcare providers to ensure a coordinated and comprehensive approach to patient management.
- **Guideline Implementation:** Advocating for and facilitating the implementation of evidence-based guidelines for SGLT2 inhibitor use in patients with T2D, HF, and CKD.^[1,2,3,6,30]
- **Medication Reconciliation:** Performing medication reconciliation to prevent errors and ensure continuity of care, particularly during transitions between care settings.

EMERGING AND FUTURE APPLICATIONS

The remarkable expansion of SGLT2 inhibitor indications has paved the way for exploring their therapeutic potential in a wider range of conditions beyond their current approvals. The ongoing research aims to further elucidate their pleiotropic effects and optimize their use in various patient populations.

1. Broader Cardiorenal Protection

- **Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF):** While evidence for HFpEF and HFrEF is robust, further studies may solidify their role in patients with HFmrEF, providing a complete spectrum of heart failure management.^[3,6,14,16,18,24]
- **Non-diabetic kidney disease (beyond established CKD):** Investigation into the use of SGLT2 inhibitors in earlier stages of non-diabetic CKD, or in specific glomerular diseases, continues to be an area of active research to prevent or delay the onset of kidney damage.^[1,6,7,28]
- **Acute Kidney Injury (AKI) Prevention:** Given their hemodynamic effects and potential to reduce kidney workload, there is growing interest in exploring the role of SGLT2 inhibitors in preventing or mitigating AKI in various clinical settings, such as before major surgeries or in acutely ill patients, though this remains largely investigational.^[25]

2. Beyond Cardiorenal-Metabolic Conditions

- **Obesity and Non-alcoholic Fatty Liver Disease (NAFLD)/NASH:** SGLT2 inhibitors lead to modest weight loss and have shown some promise in improving markers of NAFLD/NASH. Further research is needed to determine their definitive role as primary agents for these conditions.^[20]
- **Polycystic Kidney Disease (PKD):** Preliminary studies and mechanistic insights suggest SGLT2 inhibitors might have a role in slowing cyst growth and progression in PKD by

modulating renal tubular physiology, opening a new therapeutic avenue for this devastating genetic disease.^[25]

- **Diabetic Retinopathy:** While not a primary indication, some studies have explored the potential impact of SGLT2 inhibitors on diabetic retinopathy, given the systemic benefits they offer in diabetes management. More dedicated research is required to ascertain a direct protective effect.^[8]

3. Combination Therapies and Personalized Medicine

- **Novel Combinations:** Future research will likely focus on optimizing combination therapies, for example, with mineralocorticoid receptor antagonists (MRAs) or GLP-1 receptor agonists, to achieve even greater cardiorenal benefits in complex patients.^[1,2,3]
- **Biomarker-Guided Therapy:** The identification of specific biomarkers could help predict which patients are most likely to respond favorably to SGLT2 inhibitors, enabling a more personalized approach to therapy and maximizing their clinical impact.^[1,2,3]

CONCLUSION

SGLT2 inhibitors have emerged as a truly transformative class of medications, fundamentally altering the therapeutic landscape for patients with type 2 diabetes, heart failure, and chronic kidney disease. What began as a novel approach to glycemic control has evolved into a foundational therapy for comprehensive cardiorenal protection, driven by robust evidence from large-scale clinical trials.^[1,2,3,4,6,7]

Their unique mechanism of action, involving direct renal glucose excretion and a host of pleiotropic effects on hemodynamics, metabolism, and inflammation, underpins their remarkable ability to reduce cardiovascular morbidity and mortality, prevent heart failure hospitalizations across the ejection fraction spectrum, and slow the progression of kidney disease, irrespective of diabetic status.^[20,21,25,31] This "triple threat" efficacy positions SGLT2 inhibitors as indispensable agents in modern clinical practice.

While generally well-tolerated, clinicians must remain vigilant regarding potential adverse effects such as genitourinary infections and the rare risk of euglycemic diabetic ketoacidosis, requiring careful patient education and monitoring.^[5,8,25] The crucial role of clinical pharmacists in patient counseling, medication review, and interprofessional collaboration is paramount to optimizing SGLT2 inhibitor therapy and ensuring patient safety.

Looking ahead, the ongoing exploration of SGLT2 inhibitors in broader cardiorenal populations, new indications like obesity and polycystic kidney disease, and in novel combination therapies highlights their continued promise. As evidence continues to accrue, SGLT2 inhibitors are set to further solidify their position as essential tools in mitigating the global burden of intertwined cardiometabolic and renal diseases, paving the way for improved patient outcomes and quality of life.

REFERENCES

1. McMurray, J. J. V., Solomon, S. D., Docherty, K. F., et al. Dapagliflozin in patients with heart failure and mildly reduced or preserved ejection fraction. *The New England Journal of Medicine*, 2021; 385(26): 2417-2428. <https://doi.org/10.1056/nejmoa2118386>
2. Packer, M., Anker, S. D., Butler, J., et al. Effect of empagliflozin on the clinical course of heart failure with a preserved ejection fraction. *The New England Journal of Medicine*, 2021; 385(26): 2417-2428. <https://doi.org/10.1056/nejmoa2118386> (Please note: This DOI is identical to Ref 1. If this is a different paper, please provide the correct DOI.)
3. Anker, S. D., Butler, J., Filippatos, G., et al. Empagliflozin in heart failure with a preserved ejection fraction. *The New England Journal of Medicine*, 2022; 387(12): 1059-1060. <https://doi.org/10.1056/nejmoa2206286>
4. Perkovic, V., Jardine, M. J., Neal, G., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *The New England Journal of Medicine*, 2019; 380(24): 2295-2306. <https://doi.org/10.1056/nejmoa1811744>
5. Nauck, M. A. Update on developments in SGLT2 inhibitors in diabetes. *Diabetes, Obesity and Metabolism*, 2017; 19(1): 7-13. <https://doi.org/10.1111/dom.13294>
6. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., et al. Dapagliflozin in patients with chronic kidney disease. *The New England Journal of Medicine*, 2020; 383(15): 1436-1446. <https://doi.org/10.1056/nejmoa2024816>
7. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *The New England Journal of Medicine*, 2022; 388(12): 1173-1184. <https://doi.org/10.1056/nejmoa2206286>
8. Scheen, A. J. SGLT2 inhibitors for the treatment of type 2 diabetes. *Journal of Molecular Metabolism*, 2017; 6(11): 1279-1288. <https://doi.org/10.1002/dmrr.2924>
9. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Mellitus. *The New England Journal of Medicine*, 2017; 377(7): 643-653. <https://doi.org/10.1056/NEJMoa1615692> (This reference likely refers to CANVAS trial,

though the DOI provided initially was for a different journal in previous responses. The specific reference with the DOI from your list that matches 'Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Mellitus' is the one from Ref 15 and Ref 23, but the title provided in the query is different. I'll use the one from your list.)

10. Mahaffey, K. W., Neal, B., Perkovic, V., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *The New England Journal of Medicine*, 2018; 377(24): 2420-2432. <https://doi.org/10.1056/nejmoa1811744> (This is similar to Ref 15 and 23. Using the one from the list).
11. Mann, J. F. E., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy: The CREDENCE trial. *The New England Journal of Medicine*, 2020; 383(15): 1436-1446. <https://doi.org/10.1056/nejmoa2022190> (This is similar to Ref 4. Using the one from the list).
12. Cannon, C. P., McGuire, D. K., Leiter, L. A., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *The New England Journal of Medicine*, 2020; 383(15): 1436-1446. <https://doi.org/10.1056/nejmoa2024816> (This is similar to Ref 13. Using the one from the list).
13. Cannon, C. P., Leiter, L. A., McGuire, D. K., et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. *The New England Journal of Medicine*, 2020; 383(15): 1436-1446. <https://doi.org/10.1056/nejmoa2024816> (This is identical to Ref 12. If this is a different paper, please provide the correct DOI.)
14. Packer, M., Butler, J., Zannad, F., et al. Empagliflozin across the spectrum of heart failure ejection fraction. *Circulation*, 2024; 124(10): 072055. <https://doi.org/10.1161/circulationaha.124.072055>
15. Neal, B., Perkovic, V., Mahaffey, K. W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *The New England Journal of Medicine*, 2017; 377(7): 643-653. <https://doi.org/10.1056/nejmoa1811744> (This is identical to Ref 4 and 10, using the one from the list).
16. Packer, M., Anker, S. D., Butler, J., et al. Empagliflozin across the spectrum of heart failure ejection fraction. *Circulation*, 2024; 124(10): 072055. <https://doi.org/10.1056/nejmoa2409183> (This is identical to Ref 14. If this is a different paper, please provide the correct DOI.)
17. McMurray, J. J. V., Solomon, S. D., Docherty, K. F., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *The New England Journal of Medicine*, 2020;

- 383(15): 1436-1446. <https://doi.org/10.1056/nejmoa2022190> (This is similar to Ref 1. Using the one from the list.)
18. Butt, J. H., et al. Cardiovascular and renal outcomes with dapagliflozin across the spectrum of ejection fraction in heart failure: A post-hoc analysis of DAPA-HF and DELIVER. *Cardiovascular Diabetology*, 2024; 23(1): 2223. <https://doi.org/10.1186/s12933-024-02223-0>
19. Wiviott, S. D., Raz, I., Bonaca, M. P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *The New England Journal of Medicine*, 2019; 380(4): 347-357. <https://doi.org/10.1056/nejmoa1812328>
20. Hallow, K. M., & Dwyer, J. P. Renal and Cardiovascular Effects of SGLT2 Inhibitors: Beyond Glycosuria. *Molecular Metabolism*, 2022; 6(11): 101620. <https://doi.org/10.1016/j.molmet.2022.101620>
21. Vallon, V., & Thomson, S. C. Targeting SGLT2 in diabetes mellitus: Mechanisms of action and clinical implications. *Kidney International*, 2017; 92(1): 26-37. <https://doi.org/10.1016/j.kint.2017.12.027>
22. Inzucchi, S. E., & McGuire, D. K. SGLT2 inhibitors and cardiovascular risk in type 2 diabetes. *Diabetologia*, 2017; 60(9): 1618-1621. <https://doi.org/10.1007/s00125-017-4370-8>
23. Perkovic, V., de Zeeuw, D., Mahaffey, K. W., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy: The CREDENCE trial. *The Lancet Diabetes & Endocrinology*, 2018; 6(8): 606-616. [https://doi.org/10.1016/s2213-8587\(18\)30023-8](https://doi.org/10.1016/s2213-8587(18)30023-8) (This is similar to Ref 4 and 10. Using the one from the list).
24. McMurray, J. J. V., Solomon, S. D., Docherty, K. F., et al. Dapagliflozin in patients with heart failure and preserved ejection fraction. *The New England Journal of Medicine*, 2024; 385(26): 2417-2428. <https://doi.org/10.1056/nejmoa2409183> (This is identical to Ref 6. If this is a different paper, please provide the correct DOI.)
25. Sano, M. Mechanisms of SGLT2 inhibitor effects on heart failure and renal disease. *Expert Opinion on Drug Discovery*, 2023; 18(1): 1-9. <https://doi.org/10.1080/0886022x.2023.2217287>
26. Wiviott, S. D., Raz, I., Bonaca, M. P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *Journal of the American College of Cardiology*, 2020; 75(1): 154-167. <https://doi.org/10.1016/j.jacc.2020.11.029> (This is similar to Ref 19. Using the one from the list).

27. Packer, M., Anker, S. D., Butler, J., et al. Empagliflozin in heart failure with a preserved ejection fraction. *The Lancet*, 2022; 399(10323): 2213-8587. [https://doi.org/10.1016/s2213-8587\(22\)00387-4](https://doi.org/10.1016/s2213-8587(22)00387-4) (This is identical to Ref 2. If this is a different paper, please provide the correct DOI.)
28. Tuttle, K. R., et al. SGLT2 inhibition for kidney protection in patients with or without diabetes. *Clinical Journal of the American Society of Nephrology*, 2022; 17(10): 11480821. <https://doi.org/10.2215/cjn.11480821>
29. Lopaschuk, G. D., & Verma, S. Empagliflozin protects the heart from the consequences of diabetes and heart failure: a proposed mechanism. *Journal of the American Heart Association*, 2020; 9(12): 019463. <https://doi.org/10.1161/jaha.120.019463>
30. Davies, M. J., D'Alessio, D. A., Fradkin, J., et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2018; 41(12): 2669-2701. <https://doi.org/10.1111/jdi.12401>
31. Zhang, T., et al. Cardiorenal protective effects of SGLT2 inhibitors: The mechanisms beyond glucose lowering. *Scientific Reports*, 2022; 12(1): 19988-7. <https://doi.org/10.1038/s41598-022-19988-7>